Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Solid Tumors
NCT07660055Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- May 2032
- Countries
- 4
01
Overview
Phase 1, open-label trial of [177Lu]Lu-DWJ155 in breast cancer, non-small cell lung cancer (NSCLC), gastric cancer (GC) and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events of [177Lu]Lu-DWJ155 at 53 months, Incidence of dose-limiting toxicities of [177Lu]Lu-DWJ155 at 6 weeks and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
[177Lu]Lu-DWJ155
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)bladder cancer
Beyond the preview
Go deeper on NCT07660055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660055.